Search

Search Constraints

You searched for: Author/Creator Swern, Arlene

Search Results

1. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. (15th February 2017)

2. 194 Antecedent Conformity of Diagnostic and Molecular Testing Patterns in Clinical Practice for Newly Diagnosed Acute Myeloid Leukemia With American Society of Hematology and College of American Pathologists Guidelines. (11th January 2018)

3. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. Issue 1 (December 2016)